Clinical Trial Update: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study of givosiran (ALN-AS1) in patients with Acute Intermittent Porphyria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Porphyria

Drugs mentioned

• GIVLAARI (Givosiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Acute Intermittent Porphyria | Phase 1 | Status: COMPLETED